ResMed shareholders also sleep well at night

August 6, 2018

Sleep device maker ResMed this morning reported a 13% increase in revenue for the year ended 30 June 2018 together with a 27% increase in operating income. Chief Executive, Mick Farrell, was reported as saying that “we closed out the year with strong performance across all aspects of our business, from solid top-line revenue growth, driven by geographically balanced results across our entire portfolio of offerings”.  The company is well positioned for fiscal year 2019.

Resmed is one of Morgan Wealth’s core shareholdings and has produced a return of 47% for the 12 months ended 31 July 2018.

Our Top Stock Picks
Total returns on capital growth and dividends for 12 months ended 31 July 2020. Past performance is not a reliable indicator of future performance.
ResMed Inc
49.70%
Xero Ltd
38.54%
CSL Limited
18.90%
Appen Limited
16.38%
Nanosonics
12.34%
Rio Tinto Limited
8.89%
BHP Group Limited
-4.61%
Betaausustainability
-6.17%
Transurban Group
-8.17%
Altium Limited
-9.68%
ASX200 Accum Index (comparison)
-9.87%